Global Therapeutic Plasma Exchange Market Report 2024

The therapeutic plasma exchange market size has grown strongly in recent years. It will grow from $1.35 billion in 2023 to $1.47 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. The growth observed in the historic period can be credited to several factors, including the rise of immunological diseases, advancements in technology, heightened awareness and education, expanded indications for therapeutic interventions, and a deeper understanding of the underlying pathophysiology.

The therapeutic plasma exchange market size is expected to see strong growth in the next few years. It will grow to $2.12 billion in 2028 at a compound annual growth rate (CAGR) of 9.6%. The anticipated growth in the forecast period is expected to stem from various factors such as the increasing geriatric population, the availability of clinical evidence and guidelines, the regulatory landscape, enhancements in hospital infrastructure and healthcare investments, healthcare expenditure trends, and evolving reimbursement policies. Major trends expected during this period encompass personalized therapies, the integration of automation into healthcare practices, collaborative initiatives among stakeholders, and the integration of telemedicine services.

The increasing prevalence of hematological disorders is poised to drive the expansion of the therapeutic plasma exchange market in the future. Hematological disorders, or blood disorders, encompass medical conditions affecting blood and blood-forming tissues such as bone marrow, lymph nodes, and spleen. The rise in these disorders is attributed to factors such as genetic predispositions, environmental influences, and changes in lifestyle. Therapeutic plasma exchange (TPE) is employed in managing hematological disorders by removing pathogenic substances from the plasma, such as autoantibodies in autoimmune hemolytic anemia or immune complexes in thrombotic thrombocytopenic purpura, thus alleviating disease severity and enhancing patient outcomes. For example, in August 2023, as per the Leukemia and Lymphoma Society, a US-based professional organization, the projected number of myeloma diagnoses is expected to increase by approximately 2.3% from 2021 to 2023, rising from 34,920 to 35,730, respectively. Hence, the high prevalence of hematological disorders is fueling the growth of the therapeutic plasma exchange market.

Key players in the therapeutic plasma exchange market are concentrating on developing advanced products, such as automated plasma exchange systems, to enhance treatment precision, boost workflow efficiency, and simplify therapy setup and administration. Automated plasma exchange systems are medical devices engineered to perform therapeutic plasma exchange (TPE) procedures in a controlled and efficient manner. For instance, in May 2021, Baxter International Inc., a US-based healthcare company, introduced the PrisMax 2 system, an automated plasma exchange system aimed at advancing critical care delivery in patients and hospitals by eliminating harmful substances from the blood. This system addresses critical challenges in the intensive care unit (ICU), offering operational ease, intelligent efficiencies, and data-driven insights. It simplifies the complexities of delivering continuous renal replacement therapy (CRRT) and other extracorporeal therapies, improving therapy management from setup to delivery.

In April 2021, Terumo Blood and Cell Technologies, a US-based medical equipment company, partnered with CSL Plasma to introduce a new plasma collection platform at CSL Plasma U.S. collection centers. This collaboration aims to enhance the efficiency and safety of plasma collection, a vital step in producing life-saving therapies for patients with various serious and rare diseases. CSL Plasma, a US-based plasmapheresis company, offers therapeutic plasma exchange services as part of its plasma collection process at its centers.

Major companies operating in the therapeutic plasma exchange market are Medica S.p.A., Fresenius SE and Co. KGaA, Medtronic Plc., Asahi Kasei Corporation, Toray Industries Inc., Baxter International Inc., B Braun Melsungen AG, Terumo Corporation, Kaneka Corporation, Charles River Laboratories, Octapharma AG, Spectral Medical Inc., Nikkiso Co. Ltd., Haemonetics Corporation, Miltenyi Biotec Technology And Trading Co. Ltd., Macopharma SA, Cerus Corporation, Apellis Pharmaceuticals Inc., ImmunoTek Bio Centers LLC, CytoSorbents Corporation, Kawasumi Laboratories America Inc., Japan Medical Supply Co. Ltd.

North America was the largest region in the therapeutic plasma exchange market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the therapeutic plasma exchange market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the therapeutic plasma exchange market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Therapeutic plasma exchange (TPE) is a medical intervention utilized in the treatment of specific autoimmune diseases and other medical conditions. In this procedure, blood is extracted from the body, the plasma component (the fluid part of blood) is separated from the blood cells, and the blood cells are subsequently reintroduced into the body, often after being mixed with a replacement fluid. This method aids in eliminating harmful substances from the bloodstream, such as autoantibodies or toxins, which are implicated in various diseases.

The primary modalities of therapeutic plasma exchange include therapeutic plasma exchange (TPE) and double-filtered plasmapheresis (DFPP). Therapeutic Plasma Exchange (TPE) is a clinical process that involves removing plasma from the blood and substituting it with a replacement fluid, facilitating the elimination of detrimental substances or excess components. This procedure finds application in diverse medical conditions such as neurological disorders, hematological disorders, renal disorders, metabolic disorders, among others. Various technologies, including centrifugation and membrane separation, are employed in this process, catering to a range of end users such as blood collection centers, hospitals and clinics, transfusion centers, and others.

The therapeutic plasma exchange market research report is one of a series of new reports that provides therapeutic plasma exchange market statistics, including therapeutic plasma exchange industry global market size, regional shares, competitors with a therapeutic plasma exchange market share, detailed therapeutic plasma exchange market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic plasma exchange industry. This therapeutic plasma exchange market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The therapeutic plasma exchange market consists of revenues earned by entities by providing services such as patient evaluation, treatment planning, medical monitoring, and plasma separation. The market value includes the value of related goods sold by the service provider or included within the service offering. The therapeutic plasma exchange market also includes the sale of plasma separators, replacement fluids, anticoagulants, catheters and access devices, disposable consumables, and monitoring equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.